⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 30, 2024Expert Opinion on Drug Safety

Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance

F Zahedi Anya Jafari Behnam Nasiri Motlagh Seyed Hassan Hamedi Roham Salek Seyedreza Khandoozi Negin Farshchian Soodabeh Shahidsales Ahmad R Mafi Sare Hosseini Alireza Amouheidari Fatemeh Varshoee Tabrizi Nezhat Khanjani Niloofar Ahmadloo Mahdieh Dayyani Reza Khodabakhshi Mohammad Mahdi Mojahed Masoumeh Keshvari Mitra Fazl Ersi Marjaneh Mirsadraee Payam Izadpanahi Afshin Saadipoor Hamid Nasrollahi Robab Anbiaee Ali Emadi Torghabeh Alireza Keramati Seyed Ahmadreza Amiran Narges Bayat Mokhtari Ali Kermani Kazem Anvari Mahboobeh Sadeghi Ivari Malihe Dayani Amir Amirabadi Hamid Saeidi Saedi Araz Sabzvari Hamidreza Kafi Fatemeh Homaei Shandiz

View at Publisher

Ask AI

Bookmark

Share

Abstract

Background Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). This post-marketing surveillance evaluates the safety of a trastuzumab biosimilar (AryoTrust), produced by AryoGen Co. Iran in Iranian women with HER2-positive non-metastatic breast cancer (BC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zahedi et al. (2024) studied this question.

synapsesocial.com/papers/68e5e8eeb6db64358757d5f7 https://doi.org/10.1080/14740338.2024.2385483

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in MoroccoObservational Study · 2026
2Analytical Physicochemical and Functional Studies to Compare AryoTrust, a Follow-On Biologics, with the Originator Trastuzumab (Herceptin)Original Research · 2026 · 1 citations
3Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer2024 · 4 citations
4Abstract PO1-17-03: Real-world evidence of Trastuzumab biosimilars in HER2-positive breast cancer: Evaluating utilization, efficacy, and safety in Taiwan2024 · 1 citations
5Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study2024 · 2 citations

More related papers

Abstract PS1-03-25: Incidence of hypersensitivity reactions in patients receiving trastuzumab biosimilars2026
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population2024
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study2024

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,